Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core US Aggregate Bond ETF (AGG) vs Eli Lilly And Co (LLY) Price & Performance

iShares Core US Aggregate Bond ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

iShares Core US Aggregate Bond ETF vs Eli Lilly And Co — how do they compare? iShares Core US Aggregate Bond ETF trades at $97.33, while Eli Lilly And Co trades at $1,215.61 (market cap $1.10T). The key difference: Eli Lilly And Co pays a 0.56% dividend while iShares Core US Aggregate Bond ETF pays none. Which is the better fit depends on your goals.

AGGLLY
Sector
Fixed IncomeHealth
52-Week High
$101.40$1.24K
52-Week Low
$97.24$635.22
Market Cap
$1.10T
Enterprise Value
$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core US Aggregate Bond ETF

AGG trades at $97.6, up 0.17% on the day, with a neutral technical signal and bearish moving averages. Recent news highlights institutional accumulation and bond ETF inflows amid fluctuating Treasury yields. The ETF offers consistent dividends, with the latest payments scheduled for 2026.

Outlook remains tied to interest rate trends and inflation data, presenting income stability but facing pressure from rising yields. Key risks include Fed policy shifts and geopolitical impacts on oil prices, while institutional buying signals confidence in fixed-income appeal.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Core US Aggregate Bond ETF

AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.

Read more on AGG

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY